A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma

Oncogene

Volumn 32, Issue 29, 2013, Pages 3432-3442

  Yang, Y ^a,b   Zhou, L ^a,b   Lu, L ^a,b   Wang, L ^a,b   Li, X ^a,b   Jiang, P ^a,b   Chan, L K Y ^a,b   Zhang, T ^a,b   Yu, J ^a,b   Kwong, J ^a,b   Cheung, T H ^a   Chung, T ^a   Mak, K ^a   Sun, H ^a,b   Wang, H ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

APC; EEC; EZH2; H3K27me3; MicroRNA; YY1

Indexed keywords

APC PROTEIN; HISTONE H3; LYSINE; MICRORNA; MICRORNA 193A 5P; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR YY1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA; ENDOMETRIUM CARCINOMA; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TRANSCRIPTOMICS; TUMOR CELL LINE; TUMOR XENOGRAFT;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MICE; MICE, NUDE; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YY1 TRANSCRIPTION FACTOR;

EID: 84880922344     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.360     Document Type: Article

References (32)

1. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16: 8-13.
2. Nebert DW. Transcription factors and cancer: an overview. Toxicology 2002; 181- 182: 131-141. (Pubitemid 36015686)
3. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006; 25: 1125-1142.
4. Sui G. The regulation of YY1 in tumorigenesis and its targeting potential in cancer therapy. Mol Cell Pharmacol 2009; 1: 157-176.
5. Zaravinos A, Spandidos DA. Yin yang 1 expression in human tumors. Cell Cycle 2010; 9: 512-522.
6. Lu L, Zhou L, Chen EZ, Sun K, Jiang P, Wang L et al. A novel YY1-miR-1 regulatory circuit in skeletal myogenesis revealed by genome-wide prediction of yy1-mirna network. PloS one 2012; 7: e27596.
7. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J et al. NF-kappaB-YY1- miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14: 369-381.
8. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J et al. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007; 27: 4374-4387. (Pubitemid 46906562)
9. Wang H, Sun H, Guttridge DC. microRNAs: novel components in a muscle gene regulatory network. Cell Cycle 2009; 8: 1833-1837.
10. Wang L, Zhou L, Jiang P, Lu L, Chen X, Guttridge DC et al. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol Ther 2012; 20: 1222-1233.
11. Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 2006; 6: 212.
12. Aguilera O, Munoz A, Esteller M, Fraga MF. Epigenetic alterations of the Wnt/betacatenin pathway in human disease. Endocr Metab Immune Disord Drug Targets 2007; 7: 13-21. (Pubitemid 46380414)
13. Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 2011; 68: 1681-1702.
14. Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011; 30: 3391-3403.
15. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009; 10: 295-304.
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
17. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol 2008; 110: 206-215.
18. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF et al. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 2009; 124: 1358-1365.
19. Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009; 69: 9038-9046.
20. Pan Q, Chegini N. MicroRNA signature and regulatory functions in the endometrium during normal and disease states. Semin Reprod Med 2008; 26: 479-493.
21. Dawe CJ, Banfield WG, Morgan WD, Slatick MS, Curth HO. Growth in continuous culture, and in hamsters, of cells from a neoplasm associated with acanthosis nigricans. J Natl Cancer Inst 1964; 33: 441-456.
22. Richardson GS, Dickersin GR, Atkins L, MacLaughlin DT, Raam S, Merk LP et al. KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol Oncol 1984; 17: 213-230. (Pubitemid 14193208)
23. Zysman M, Saka A, Millar A, Knight J, Chapman W, Bapat B. Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res 2002; 62: 3663-3666. (Pubitemid 34728844)
24. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE et al. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 2009; 8: 1367-1372.
25. Andl CD. The misregulation of cell adhesion components during tumorigenesis: overview and commentary. J Oncol 2010 pii: 174715.
26. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002; 21: 7981-7990. (Pubitemid 35430609)
27. Ko CY, Hsu HC, Shen MR, Chang WC, Wang JM. Epigenetic silencing of CCAAT/ enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem 2008; 283: 30919-30932.
28. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17: 2613-2618.
29. Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998; 152: 1107-1123. (Pubitemid 28221862)
30. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010; 18: 181-187.
31. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA- 34. Cancer Res 2010; 70: 5923-5930.
32. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009; 136: 640-651.